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question bears significant economic and sociopolitical implications and has been contentious in many
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conception of need used. We demonstrate how these principles can differ not only in content but also in the
relative importance they are accorded by governments. Wide variation in ART public funding policy might be
better understood in this light. We conclude with some inter-country comparison. New Zealand and Swedish
policies are uncommonly transparent and thus demonstrate particularly well how the arguments we explore
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Abstract Should there be a female age limit on public funding for assisted 
reproductive technology (ART)? The question bears significant economic and 
sociopolitical implications and has been contentious in many countries. We 
conceptualise the question as one of justice in resource allocation, using three much-
debated substantive principles of justice—the capacity to benefit, personal 
responsibility, and need—to structure and then explore a complex of arguments. 
Capacity-to-benefit arguments are not decisive: There are no clear cost-effectiveness 
grounds to restrict funding to those older women who still bear some capacity to 
benefit from ART. Personal responsibility arguments are challenged by structural 
determinants of delayed motherhood. Nor are need arguments decisive: They can 
speak either for or against a female age limit, depending on the conception of need 
used. We demonstrate how these principles can differ not only in content but also in 
the relative importance they are accorded by governments. Wide variation in ART 
public funding policy might be better understood in this light. We conclude with some 
inter-country comparison. New Zealand and Swedish policies are uncommonly 
transparent and thus demonstrate particularly well how the arguments we explore 
have been put into practice. 
 
Keywords Reproductive techniques, assisted; Ethical analysis; Distributive justice; 
Health care rationing; Health policy; Need; Capacity to benefit; Disinvestment 
 
Introduction 
Levels of public funding for assisted reproductive technology (ART) vary widely 
internationally. Some countries do not publicly fund ART at all, while others do so to 
different degrees and for different sub-populations (Chambers et al., 2009). Many 
countries that do publicly fund ART do so with a female age limit. For example, 
women over the following ages usually cannot access ART public funding in their 
respective countries: 37, the Southern Health Care Region of Sweden (Lindström and 
Waldau 2008); 39, New Zealand (Farquhar, Wang, and Sullivan 2010); 39, United 
Kingdom (National Collaborating Centre for Women’s and Children’s Health 2004); 
45 (or 51 with donor oocytes), Israel (Birenbaum-Carmeli and Dirnfeld 2008, 184). 
By contrast, Australia’s ART public funding policy may be unique in the world in not 
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featuring any female age limit (Assisted Reproductive Technologies Review 
Committee 2006, 50). Should there be a female age limit on ART public funding? 
 
The question is important for at least two reasons. First, it may have significant 
economic implications for the health care system of the country concerned. For 
instance, Australian expenditure on Medicare benefits for ART increased from 
AUD39.3 million in 2000 to AUD248.3 million in 2009 (Medicare Item Reports 
n.d.).
1
 The sustainability of such expenditure is questionable. A female age limit on 
ART public funding represents one means by which to curb expenditure. Indeed, 
savings would increase as ART is increasingly sought by older women. In 1992, 9.3 
percent of all women initiating in vitro fertilisation (IVF) cycles in Australia and New 
Zealand were aged 40 and over (Lancaster, Shafir, and Huang 1995).
2
 By 2007, this 
proportion had steadily increased to 22.8 percent (Wang et al. 2009).
3
 The question of 
a female age limit on ART public funding also bears significant sociopolitical 
implications. It raises questions of discrimination. Is a female age limit on ART 
public funding discriminatory—on the basis of sex, age, or medical condition? Does it 
discriminate between individuals on the basis of a characteristic that is properly 
irrelevant in the prevailing context, therein perpetrating an injustice? 
Watt et al. chronicle how “the public subsidy of ART has been a perennially 
contentious health policy issue in Australia” (2011, 201), just as it has been in other 
countries. In this paper, we invite consideration of the possibility that historical and 
geographical variation in ART public funding policy reflects underlying variation in 
conceptions of justice when it comes to resource allocation. 
Mladovsky and Sorenson (2010) review a number of differing government rationales 
for ART public funding and its multivarious restriction. Governments often fail to 
make explicit these rationales, and so too their underlying conceptions of justice. 
There is a recognised need for research into these (Mladovsky and Sorenson 2010), 
and we intend this paper to contribute toward meeting that need. We conceptualise the 
question of whether there should be a female age limit on ART public funding as one 
                                                 
1
 These amounts use calendar years and combine benefits paid under ART Medicare item numbers 
13200, 13203, 13206, 13209, 13212, 13215, 13218, and 13221. 
2
 9.3 percent = (451 + 54) / (4,878 + 572) 
3
 In order to observe the steadiness of the increase, see intervening reports, all available at 
http://www.npsu.unsw.edu.au/preruweb.nsf/page/Assisted+Reproduction+Technology+Reports. 
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of justice in resource allocation and confine the scope of our paper accordingly. While 
the paper may prompt still more fundamental questions concerning the nature of 
medicine and the scope of citizens’ responsibilities to one another, it will not address 
these directly. We also limit the paper’s discussion to ART that is intended to 
overcome what is normally understood by “medical” or “clinical” infertility, i.e., a 
man and a woman experiencing difficulty in achieving a live birth. When ART is used 
for different reasons, female age may well be relevant in different ways and to 
different degrees. 
We begin by exploring a complex of arguments for and against a female age limit on 
ART public funding. We bring order to that complex by expounding each argument 
under the heading of “capacity to benefit,” “personal responsibility,” or “need.” These 
terms are common in just resource allocation theory, but they are often used 
differently. Some theorists (Mooney and Houston 2004) fully equate “capacity to 
benefit” with “need,” while others do not (Cookson and Dolan 2000; Culyer 2001, 
2007; Hope, Osterdal, and Hasman 2010). In this paper, we treat all three terms as 
provisionally distinct and explore some of their contested meanings. 
Toward the end of the paper, we summarise the different ART public funding policies 
of Australia, New Zealand, and the Southern Health Care Region of Sweden, then 
articulate these more formally in terms of the arguments we explore. The New 
Zealand and Swedish policies are uncommonly explicit about their rationales and 
even their underlying conceptions of justice. As such, they demonstrate particularly 
well how the arguments we explore have been put into practice. When compared with 
Australian policy, they also demonstrate how policy can be underpinned by different 
conceptions of justice. 
We conclude by formulating questions with which, in light of our exploration, the 
question of ART resource allocation might be equated. In short, how should a 
government conceptualise—then assign relative levels of importance to—infertility-
related need, infertility-related personal responsibility, and the capacity to benefit by 
ART rather than some other form of help? Variation in ART public funding policy 
might be better understood as reflecting different answers to this question. 
 
Principles of Justice: The Capacity to Benefit, Personal Responsibility, and Need 
Aristotle’s principle of justice—equals should be treated equally—is merely formal 
insofar as it declines to specify precisely who are equals (Beauchamp and Childress 
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2009). In just resource allocation theory and practice—relating both to ART and to 
health care more broadly—equals have been variously identified by, among other 
things, their capacity to benefit from treatment, their degree of personal responsibility 
for their health problem, and their degree of need (Beauchamp and Childress 2009; 
Cookson and Dolan 2000). In other words, the following has been variously asserted: 
 Equals in their capacity to benefit from treatment should be treated equally. 
 Equals in their degree of personal responsibility for their health problem 
should be treated equally. 
 Equals in their degree of need should be treated equally. 
In this way, the capacity to benefit, personal responsibility, and need represent not 
merely formal but, by contrast, material or substantive principles of justice, principles 
by which resources might be justly allocated.
4
 We now use these three substantive 
principles of justice to differentiate and explore arguments for and against a female 
age limit on ART public funding. 
 
Capacity-to-Benefit Arguments 
Reduced Cost-Effectiveness 
Perhaps the most widely used argument in favour of some female age restriction on 
ART public funding goes as follows: ART success rates decline with female age. In 
this way, older women can be said to demonstrate a comparatively reduced capacity 
to benefit from ART. This results in ART being less cost-effective for older women. 
By itself, this does not commend restriction; the argument must continue as follows: 
When undertaken by older women, ART is insufficiently cost-effective insofar as 
resources might have been used to greater effect. 
In order to more thoroughly assess this argument, we must first canvass relevant 
empirical data. Australia’s Assisted Reproductive Technologies Review Committee  
observed that “[t]here is undisputed evidence that [female] age is the single most 
important factor in determining the success of ART” (2006, 67). In this paper, we 
define ART success as a live delivery (live birth). Figure 1 plots the success rate of 
autologous in vitro fertilisation (IVF) cycles declining with female age. (In autologous 
cycles, women use their own oocytes, not those of a donor.) The trend, if not quite its 
                                                 
4
 “Justly” might be substituted with “fairly,” “equitably,” or even “best” without changing the intended 
meaning. 
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magnitude, is shared by fresh and frozen-thaw cycles alike: The success rate 
decreases as female age increases. A large body of evidence confirms this trend, in 
which the age of the woman at the point of oocyte retrieval appears to most heavily 
influence the probability of treatment success (Watt et al. 2011). A lower probability 
of treatment success can be regarded as a smaller capacity to benefit from treatment.  
The success rates of donor cycles tend not to differ with female age, i.e., the age of 
the oocyte recipient. This significantly weakens capacity-to-benefit arguments for a 
female age limit in the case of donor cycles. Israel’s age limit of 45 or 51 with donor 
oocytes likely registers this. However, the use of donor oocytes also introduces 
additional ethical considerations that make it an exception to the rule of declining 
success rates, which this paper does not have space to adequately address. For 
example, conflicts of interest may exist between the clinician, donor, and recipient 
(Ethics Committee of the American Society for Reproductive Medicine 2009). Also, 
given particular financial arrangements, “the welfare of the fee-paying recipient 
patient may be placed above that of the egg donor” (Heng 2008, 414). Furthermore, 
parties may disagree concerning the disclosure of the donor’s identify (Burr and 
Reynolds 2008)—both to the recipient and to the child. The donor must risk her 
health without personal benefit: Is this problematic? How can we ensure that donation 
is sufficiently informed and voluntary (Black 2010)? Ought donation also to be 
reimbursed? If so, then how can donors be recruited without exploitation (Kalbian 
2011) and without the commodification of oocytes (Blyth 2002)? Do we wrong a 
child by wilfully giving it life at some distance from one of its genetic parents (Frame 
2008)? What risks does donation pose to relationships, both relationships among 
partners and relationships with the child? 
When both successful and unsuccessful cycles are considered, the resources required 
to achieve a live birth by means of ART increase substantially with female age. 
Griffiths et al. (2010) estimated that the incremental monetary cost of achieving a live 
birth on the first cycle of treatment ranged from AUD27,373 for women aged 30–33 
to AUD130,951 for women aged 42–45. For estimates comparable in trend and 
magnitude, see Chambers (2006). 
From a certain perspective—one trained foremost on allocative efficiency—ART for 
older women can seem to represent a poor use of public funds. However, this 
conclusion meets at least two counterarguments, even from within the perspective of 
allocative efficiency: (1) ART for older women remains cost-effective relative to 
8 
 
other health care; (2) alternatively, the true cost-effectiveness of ART is unusually 
difficult to determine due to conceptual difficulties. We now explore each of these 
counterarguments in turn. 
Other things being equal, ART may well be less cost-effective when undertaken by 
older women, but nonetheless it may remain highly cost-effective relative to other 
health care (in which case restriction would not be warranted). The following cost-
effectiveness analysis certainly suggests this. 
Griffiths et al. (2010) found that the incremental cost per live birth at a maternal age 
of 42–45 years and on a second treatment cycle was AUD187,515. This was the 
largest figure in their base case analysis (their “worst-case” scenario). Australian life 
expectancy at birth is 81.5 years per person (Australian Bureau of Statistics 2008). 
Therefore, even when least effective, the incremental cost of ART per life-year gained 
is a mere AUD2,301 (AUD187,515 / 81.5). 
In calculating the benefit provided by any health care, we may wish to incorporate 
some preference for current over future health. We might thereby apply a discount 
rate to the future life-years gained by ART as a measure of the extent to which 
individuals aggregated across society are willing to forgo current benefits in order to 
obtain future ones. People who place less importance on future costs and outcomes 
will apply a higher rate of discount. 
Applying a customary 5 percent discount rate, 81.5 future life-years equates to 20.6 
discounted life-years gained.
5
 Thus, the incremental cost per life-year gained now 
equates to AUD9,103 (AUD187,515 / 20.6). In this light, ART appears somewhat less 
cost-effective than it does above, when we do not apply a discount rate. Applying a 10 
percent discount rate, ART appears less cost-effective again (AUD187,515 / 11.0 = 
AUD17,047). However, even at this uncommonly high discount rate, ART compares 
acceptably with other previously funded health care (notwithstanding complexities we 
soon touch on). If Australia were considering a pharmaceutical for public funding, the 
above amounts would likely be regarded as well within the range that the Australian 
government is willing to pay for an additional life-year gained. Indeed, incremental 
costs per life-year gained of up to AUD50,000 and more have been considered 
acceptable, judging by past public funding decisions (Cleemput et al. 2011). 
                                                 
5
 We calculate this by successively dividing future life-years by increasing powers of 1.05 and then 
summing. 
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ART’s life-year benefit should be offset according to the magnitude of any survival 
and quality-of-life deficits observable over the lifespan relative to non-ART peers. If 
we assume that, throughout life, some individuals born via ART suffer some quality-
of-life deficit relative to their non-ART peers, then this will increase ART’s 
incremental cost per quality-adjusted life-year (QALY) gained. There is significant 
debate concerning the relative health of those born via ART, but some current major 
findings are as follows: 
 Children born following ART (particularly singletons) are at increased risk of 
some birth defects compared to spontaneously conceived children (Hansen et 
al. 2005; Reefhuis et al. 2009). 
 In singleton ART infants, there is an increased risk of perinatal mortality, low 
birth weight, and preterm birth compared to singletons conceived 
spontaneously; there are few differences in these outcomes between twins 
conceived spontaneously and those conceived with ART (Bower and Hansen 
2005). 
 No negative effect on neurodevelopmental outcomes (neuromotor, cognitive, 
language, and behaviour outcomes) has been identified but studies with longer 
follow-up are required (Middelburg et al. 2008).  
The difficulties associated with undertaking such studies should be noted. For 
instance, are the findings attributable to ART or to the underlying infertility? How 
severe is the confounding conferred by multiple births? Do age, socioeconomic status, 
or other parental attributes contribute to the findings? Studies with longer follow-up 
are required, as are those that track the consequences of changing clinical practices 
and new technologies (such as oocyte vitrification and preimplantation genetic 
diagnosis). Current evidence may be too ambiguous to include in economic 
evaluation. However, suppose that we do include it. While the magnitude of increased 
risks for ART-born children is significant in relative terms, these risks are still very 
small in absolute terms. As such, they are unlikely to greatly increase ART’s 
incremental cost per QALY gained (just focusing on those QALYs gained by the 
child). Therefore, even accommodating some quality-of-life deficit for those born via 
ART, it is likely that we could still consider ART to represent comparatively good 
value for money.  
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But what complicates and undermines the above cost-effectiveness analysis? 
Mladovsky and Sorenson contend that the economic arguments for and against 
publicly funding ART are currently inconclusive due to difficulties that are largely 
conceptual: Economic assessments frequently fail “to sufficiently capture the broader 
costs and benefits of IVF” (2010, 114). What are we to include among the benefits 
and harms involved in both successful and unsuccessful ART? For instance, a life-
year gained for a person who would not otherwise have existed (but for ART) may 
differ conceptually in some important way from a life-year gained for a living person. 
For instance, the benefit of 81.5 life-years mooted above does not in itself relate to the 
benefit enjoyed by the infertile patient but rather to that enjoyed by his or her 
offspring. Devlin and Parkin argue that ART’s benefit should be assessed in terms of 
the increased quality of life enjoyed by those (already living) who undertake ART: 
QALYs are intended to capture improvements in health among patients. 
They are not appropriate for placing a value on additional lives. Additional 
lives are not improvements in health; preventing someone’s death is not the 
same as creating their life and it is not possible to improve the quality of life 
of someone who has not been conceived by conceiving them. CUA [cost-
utility analysis] might instead proceed by focusing on the health related 
improvements in quality of life by prospective parents seeking treatment for 
infertility (Devlin and Parkin 2003, S4). 
A central question is whether to include among ART’s benefits those enjoyed by the 
child, those enjoyed by the parents, or both. (The same question applies to ART’s 
risks of harm, which might be counted negatively on the benefits side.) Including only 
those benefits (and risks of harm) applicable to the parents (namely those already 
living) has the potential to greatly reduce the cost-effectiveness of ART. This applies 
to older and younger women alike. Conversely, ART would appear even more cost-
effective relative to other health care if its benefits were considered to include the sum 
of quality-of-life improvements for patients in addition to the life-years gained for 
children born. Therefore, much turns on what is included among ART’s benefits. 
Any quality-of-life deficits should be counted negatively on the benefits side. These 
might be accentuated for those patients whose ART fails, for instance. There is some 
evidence (albeit limited) that leaving a program of treatment childless confers 
“clinical[ly] relevant emotional problems” on a subset of women (Verhaak et al. 
2007). Conversely, Ryan  measured some psychological benefit “in going through the 
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service, even if you leave it childless” (1996, 196). Does the opportunity of trying for 
a baby via ART, irrespective of the outcome, itself constitute a benefit?  
Conceptual difficulties in ART cost-effectiveness analysis cut both ways, providing 
reasons for caution in both availing and restricting ART funding solely on cost-
effectiveness grounds. However, if one chooses to proceed despite these difficulties, 
then available cost-effectiveness analysis, combined with contestable assumptions on 
the benefit achieved by ART, can be used to support the argument that ART for older 
women remains sufficiently cost-effective relative to other health care. 
 
Medical Futility 
The generally reduced capacity of older women to benefit by ART is relevant to age-
restriction debates not only for its negative impact on comparative cost-effectiveness 
but also because it prompts questions about medical futility. These questions are 
important because futile treatment can be considered not merely wasteful but 
potentially harmful. We might venture that the providers (and funders) of futile 
treatment wrong their patients and not simply those whom expended resources might 
otherwise have helped. There is a marked conceptual—and, we would say, ethical—
difference between (1) prioritising one patient above another in order to maximise the 
aggregated net benefit and (2) seeking to protect a patient from harms that are risked 
merely for the sake of a vanishingly small probability of benefit. 
At what point should ART be considered futile? How small must be the capacity to 
benefit? That is, how small must be the probability of a live birth, or (better) the 
increase in that probability, or the associated increase in the patient’s quality of life? 
Australia’s Assisted Reproductive Technologies Review Committee  contended that 
[g]iven the success rate of less than 2 percent noted in the most recently 
available age-specific data, it is not clinically appropriate to initiate a new 
cycle of in vitro fertilisation (IVF) treatment in women using their own eggs 
at 44 years and over (2006, 16).
6
 
The rationale of “clinical appropriateness” implies a concern to avoid treatment that is 
futile and not merely cost-ineffective. Considering harms and the point at which they 
ought not to be risked for only very small benefits can strengthen the argument for 
                                                 
6
 Australian ART public funding policy is itself silent on this issue. As we explain below, Medicare 
covers part of the cost of all ART that an appropriate clinician deems to be medically needed. 
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some female age restriction on ART public funding. However, in attempting to assess 
the magnitude of potential harms and benefits, we run into the same conceptual 
difficulties facing cost-effectiveness analysis. We also run into a surprising lack of 
empirical data on the age-relative risks of harm that ART may incur (Bewley, Foo, 
and Braude 2011; Watt et al. 2011). (Independent of ART, older women face greater 
risks of complications when pregnant. Independent of female age, ART poses 
particular risks. In this way, a linked-evidence approach could be used as part of an 
assessment of ART’s risks of harm.) 
 
Personal Responsibility Arguments 
What personal responsibility do we bear for our health and how, if at all, should this 
impact on how our health needs are assessed and prioritised in the provision of public 
funding? This is a contentious question. Older women may be held personally 
responsible for their diminished fertility to the degree that some chosen deferral 
contributed to it. Their claim on public funding may thereby be undermined. This 
broadly equates to a fair-innings argument of the kind “you had your chance.” It 
might also lead to an argument concerning moral hazard, in the economic sense: By 
rescuing those whose chosen delays have contributed to diminished fertility, does 
ART public funding for older women thereby encourage more people to make the 
same risky choices? 
Though defensible, these arguments should guard against callousness. They should 
also consider what Steele  calls “underlying structural determinants of older 
motherhood and foreshortened reproductive careers” (2011, 1). Prominent among 
these determinants may be “economic uncertainty for young people in Western 
countries,” considered in the light of, among other things, “non-permanent 
employment arrangements for individuals and, where relevant, their partners; higher 
education debt; and the high cost of home ownership (and consequent delay in, or 
nonattainment of, first home ownership).” Such structural determinants, or risk factors 
for delayed childbearing, challenge arguments that presume a full, and thereby fully 
accountable, reproductive freedom. 
 
Need Arguments 
Questions concerning personal responsibility for one’s medical needs tend to depend 
on answers to more fundamental questions: namely, questions concerning how 
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medicine should conceptualise, and accordingly prioritise, different needs and 
capacities to benefit. When is one need greater than another? In other words, what 
constitutes a medical need? One answer to this question speaks in favour of some 
female age restriction on ART public funding, while alternative answers speak against 
such restriction. 
 
Reduced Disruption to Normal Health 
On one conception, need increases with the degree of disruption to normal health. 
Daniels (1985) has proposed that normal health, in turn, should be conceptualised in 
terms of “species-typical functioning” or the “normal opportunity range” that, as a 
species, human beings demonstrate. Hope, Osterdal, and Hasman expand on this 
conception of need: Person A needs health care X “in order to function normally: that 
is, above some critical, or threshold, level” (2010, 473). (Notably, this formulation 
gives more scope to a culturally relative threshold.) We can apply the work of Hope et 
al. to the context of infertility: An infertile person’s need can be proportionally related 
to the normal probability of a live birth minus the person’s specific probability of a 
live birth (all without ART). 
Along these lines, it might be argued that infertile younger women generally stand in 
greater need than infertile older women because, for younger women, the normal (or 
population average) probability of a live birth is generally higher than it is for older 
women. In other words, diminished fertility is more normal in older women, therefore 
the disruption to normal health that it betokens—and the corollary medical need that 
arises—is comparatively reduced. This argument depends on: 
(1) a view that medicine ought to restore health to normal levels but not take it 
beyond these levels, at least on some fundamentals; and 
(2) an endorsement of declining fertility with female age as one such fundamental 
or, in other words, as important to a degree that medicine would do wrong not to 
defer to it in some way. 
Both (1) and (2) are defensible, though contestable and philosophically involved 
(Carter and Braunack-Mayer 2011). 
 
Equally Important Opportunity 
On a competing view, medicine ought to aid people in need without reference to the 
normal or the natural. It ought to act simply out of mercy, for instance, or in line with 
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social norms. On this view, medicine ought to overcome not so much disruptions in 
normal health but, for instance, limits to important opportunities. Relative to infertile 
younger women, then, infertile older women stand in equal, not reduced, need by 
virtue of the fact that the opportunity to have a child may be equally important for 
them. 
A need, such as that for a child, might be taken to exist whenever someone testifies to 
it with sufficient moral force. This might be to say “whenever it would strike us as 
merciless or cruel to deny the need.” In this way, women might lay claim to a need 
that is independent of age. Likewise, even some relegation of fertility from the status 
of need to that of mere desire might weaken equally the claims of older and younger 
women on ART public funding. 
Rawlins and Culyer suggest that sound claims exist “to give a higher priority to novel 
treatments for conditions for which no alternative specific forms of therapy are 
currently available, or to conditions associated with social stigma” (2004, 226). 
Rawlins and Culyer imply that, in such cases, need is accentuated and that, as such, it 
is especially important for cost-effectiveness analysis not to dominate decision-
making. It can be argued that ART is a novel treatment, with no direct comparator, 
and that infertility is associated with social stigma (Slade et al. 2007). On both of 
these scores, younger and older women may stand equally in need. 
 
Increased Severity and Increased Urgency 
The severity of a problem may be taken to increase, by degree, the medical need that 
exists in light of it. Relative to younger women, older women generally suffer an 
increased severity of infertility by virtue of their lower probability of a live birth 
without ART. In this regard, they may lay claim to an increased need. Hope et al. 
identify in such thinking the “poor initial state” conception of need: Person A needs 
health care X “in order to avoid harm” (Hope, Osterdal, and Hasman 2010, 473). 
Again, applying the work of Hope et al. to the context of infertility, an infertile 
person’s need can be proportionally related to the number one minus the person’s 
specific probability of a live birth without ART (expressed as 0.3, say). The number 
one signifies the best imaginable health and, on this conception of need, replaces 
normal health (or the normal probability of a live birth without ART), which the 
“normal functioning range” conception of need used (Hope, Osterdal, and Hasman 
2010, 473). 
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Furthermore, an older woman’s lower probability of a live birth with ART, not 
without it, may be precisely the thing to entitle her to more, and not less, funding (in 
the form of additional funded treatment cycles, for instance). This can follow the 
egalitarian aim of trying to return everyone to an equal (fertility) footing, which may 
underlie ART funding in the first place. 
The severity of infertility may also be regarded as proportional to its duration. Here, 
too, older women may lay claim to a greater severity of infertility (and therein need) if 
they have generally been infertile for longer. 
Like the severity of a problem, the urgency of a problem may be taken to increase, by 
degree, the medical need that exists in light of it. On average, an older woman’s 
probabilities of a live birth, both without ART and with it, drop more quickly than do 
those of a younger woman. In this respect, an older woman’s need for treatment can 
be regarded as more urgent and, therein, greater. Furthermore, menopause may be 
seen as a critical threshold. If medicine ought only to restore “species-typical 
functioning” (Daniels 1985), then it ought not to extend female fertility beyond its 
“species-typical” endpoint. If menopause is seen as a critical threshold in this respect, 
then a woman’s need for ART may become more urgent, and therefore greater, the 
closer she approaches that threshold. 
 
Interactions Between Capacity-to-Benefit and Need Arguments 
Thus far, we have explored a series of arguments for and against a female age limit on 
ART public funding. We have done so largely in relation to concepts of the capacity 
to benefit and need. Complexities exist not only within each of these concepts, but 
also in their potential interactions. For instance: 
Person A stands to benefit more by treatment X than person B. A therein 
needs X more than B, though B may need some form of help more than A. 
Here is a variation on this observation: 
You cannot ever need futile treatment. Though you need help, you do not 
need that help. 
If we accept this observation and the conception of need that it implies, then older 
women generally need ART less than younger women precisely by virtue of their 
reduced capacity to benefit (considered in terms of lower probabilities of a live birth). 
The conception of need at work in this observation is consistent with the “significant 
gain” conception of need identified by Hope et al.: Person A needs health care X “in 
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order to improve health significantly” (Hope, Osterdal, and Hasman 2010, 473). 
Again, applying their work to the context of infertility, an infertile person’s need can 
be proportionally related to the person’s specific probability of a live birth with ART 
minus the person’s specific probability of a live birth without ART. Here, need is 
essentially identified with, or reduced to, the capacity to benefit from treatment. 
 
How Policies Incorporate These Arguments 
In the next section, we demonstrate how three current ART funding policies 
incorporate the above arguments in the form of a range of criteria that any claim on 
ART public funding must either meet or be prioritised against. As such, we focus on 
different ways in which female age has been considered relevant (or irrelevant) to the 
just allocation of resources within the context of ART. We examine in turn the 
different policies of Australia, New Zealand, and the Southern Health Care Region of 
Sweden. First, we describe key policy elements, and then we articulate each policy 
more formally in terms of the arguments explored above. 
 
Australia 
Australia’s Assisted Reproductive Technologies Review Committee observed that 
“Australia appears to be unique in not limiting access to funding for ART services” 
(2006, 50). On its own, this comment is misleading. ART funding continues to be 
limited in Australia on at least three fronts. First, funding is officially available for 
medical infertility only. (In practice, this requirement is interpreted differently by 
different health care providers.) Second, a co-payment is frequently required: Patient-
borne out-of-pocket costs vary across clinics, ranging from near-zero to 
approximately AUD2,500 for the first full cycle in a year, AUD2,000 for subsequent 
cycles, and AUD1,000 for frozen-thaw cycles (Repromed n.d.). By comparison, 
government expenditure is approximately AUD2,600–2,900 for an individual’s first 
full treatment cycle in a year, AUD2,500–2,800 for each subsequent cycle, and 
AUD600 for frozen-thaw cycles (MBS Online n.d.). Third, for any one person, 
funding is capped annually but not over the course of a lifetime. (Reimbursement 
under the Extended Medicare Safety Net is capped annually; base reimbursement 
under the Medicare Benefits Scheme is not.) 
Australian ART funding policy features no reference to female age. Nowhere is the 
capacity to benefit from ART referenced. Implicitly, then, that capacity is either 
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neglected, actively rejected as irrelevant, or accommodated within the view that ART 
is always worthy of funding on grounds of allocative efficiency. Futile ART is 
presumed to be avoided by good medical practice and not funding policy. 
Australian ART funding varies neither with a person’s capacity to benefit nor with 
one’s degree of need. All women are implicitly accepted as equally in need provided 
that they or their male partner are medically infertile. The conception of medical need 
implicit is one of “normal functioning range,” with the normal range being identified 
with perfect fertility before (normal) menopause. 
In contrast to Australia, both New Zealand and the Southern Health Care Region of 
Sweden restrict the amount of ART public funding that is available to an individual 
over a lifetime. Moreover, they restrict eligibility for funding partly on cost-
effectiveness grounds, using numerous criteria that are both explicit and (what is 
rarer) explicitly justified. Among these criteria, female age figures heavily, primarily 
due to its impact on ART cost-effectiveness. 
 
New Zealand 
Since 2000, New Zealand has used a range of criteria to score a person’s claim on 
ART public funding (Gillett, Peek, and Herbison 2012). The current criteria include: 
chance of pregnancy without treatment (or “diagnosis”); female age; duration of 
infertility; number of children; and sterilisation status (Farquhar, Wang, and Sullivan 
2010; Gillett, Peek, and Herbison 2012). Only claims that reach the threshold score 
receive funding, which covers a maximum of two treatment cycles in total. Gillett and 
Peek, who first devised the scoring system, explain that: “It is intended to benefit 
those who are most in need of therapy, but balanced by a system that will ensure 
maximum benefit” (2000, 24). In other words, justice is regarded as adequately 
achieved when, other things being equal, equal funding is given to those with an equal 
need and an equal capacity to benefit. 
It is not clear which criteria are intended to score need. On our interpretation, a 
person’s need is scored by first calculating the probability of pregnancy without ART 
(or “diagnosis”) using a separate, more clinically detailed scorecard. In this way, the 
New Zealand scoring system implicitly accepts the argument that, next to younger 
women, older women stand in increased need when they demonstrate a lower chance 
of falling pregnant without ART. This suggests that a “poor initial state” conception 
of need is in tow. The need score is then, in effect, later modified under (at least) the 
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criterion of duration of infertility. If this is the case, then the New Zealand scoring 
system also accepts the argument that, next to younger women, older women stand in 
greater need if they have been infertile for longer. 
Gillett et al. report that female age was the only criterion to cause “considerable 
disquiet in the public submissions that preceded” introduction of the scoring system: 
“The main argument was that older women had the most urgent need” (Gillett, Peek, 
and Herbison 2012, 139). On its own, the New Zealand scoring system does not 
accept this argument. A person is afforded ART public funding when one reaches the 
threshold score and not before. A projected decrease in the probability of pregnancy, 
both with and without ART, only decreases the time required for the threshold score 
to be reached—it does not change the score itself. However, Gillett et al. report that 
ART public funding is sometimes provided under “clinical override,” when 
exceptions are made in view of system imperfections (Gillett, Peek, and Herbison 
2012, 135). Clinical override is applied (less than 10 percent of the time) when, for 
instance, waiting for points to accumulate would sufficiently decrease the probability 
of treatment success. In practice, clinical override enables a clinician to accept the 
argument that older women stand in greater need in cases of increased urgency. 
In New Zealand, need-based arguments are outweighed by a capacity-to-benefit 
argument, however. Gillett and Peek proposed that “criteria should give preference to 
those who are most likely to benefit,” therefore “factors that are known to have an 
influence on the probability of a successful outcome ... should be heavily weighted in 
the point system” (1997, 20). The sole criterion of female age is used to estimate and 
correspondingly score the probability of treatment success (listed as pregnancy, not a 
live birth). In calculating the strength of claims on ART public funding, women are 
allocated point-multipliers of 1.0, 0.5, or 0.1 if their age is ≤ 39, 40–41, or ≥ 42, 
respectively. Theoretically, then, a 39-year-old woman is 10 times more likely to 
receive ART public funding than her 42-year-old counterpart. While the New Zealand 
scoring system is designed to use female age as a prioritising criterion, in practice 
female age functions as a threshold criterion: Current funding levels dictate a 
threshold of 65 points—only women aged 39 years and under can score as much and 
thereby access ART public funding. 
Gillett and Peek have explicitly stated that the point-multipliers are intended to reflect 
the probability of treatment success and not the degree of need (which, on one 
argument above, is generally higher for younger women by virtue of infertility 
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constituting for them an increased disruption in normal health) (Gillett and Peek 1997; 
Gillett, Peek, and Herbison 2012). As such, the New Zealand scoring system, with 
what functions as an age limit, implicitly accepts the argument that, by virtue of their 
reduced capacity to benefit by ART, older women use ART resources at too great an 
opportunity cost; that is, those same resources might benefit other (younger) women 
more. Implicit in the funding threshold of 65 points is also a rejection of the argument 
that the capacity of older women to benefit by ART is, though less than that of 
younger women, nonetheless sufficient to justify expenditure in view of its cost-
effectiveness relative to other forms of health care. 
Gillett, Peek, and Herbison (2012) suggest that the capacity to benefit from treatment 
is captured by two criteria taken together, namely female age (as a proxy for the 
chance of pregnancy with treatment) and the chance of pregnancy without treatment 
(which, above, we identify with need). Analysing both treatment and non-treatment 
outcomes, Gillett et al. demonstrate that the New Zealand scoring system largely 
succeeds in selecting for funding (1) those who are most likely to achieve a live birth 
with ART and (2) those who are least likely to achieve a live birth without ART.
7
 The 
scoring system is thereby largely effective in using as a substantive principle of 
justice the capacity to benefit from treatment. Gillett et al. implicitly regard ART’s 
benefit as an increase in the probability of a live birth. 
 
The Southern Health Care Region of Sweden 
The Southern Health Care Region of Sweden uses a range of threshold (not 
prioritising) criteria in order to allocate ART public funding. The criteria include: 
female age; male age; female body mass index (BMI); follicle-stimulating hormone 
(FSH) level; duration of infertility; number of children; and previous ART funding 
(Lindström and Waldau 2008). In order to qualify for funding, women must be aged 
37 or under. The “guiding principle” behind this criterion is openly identified as 
“[c]ost-effectiveness combined with a normal-deviant scale” (Lindström and Waldau 
2008, 182). In other words, evidence of differing cost-effectiveness (owing to 
differing effectiveness) is explicitly cited as justification for the age limit. Older 
women are thereby, as in New Zealand, denied funding on the basis of their reduced 
                                                 
7
 An Australia−New Zealand comparison of ART success rates can be cited in support of (1) (Farquhar 
et al. 2010). 
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capacity to benefit and the opportunity cost that this entails. Implicit again within the 
broader Swedish policy is a rejection of the argument that ART for older women is 
sufficiently cost-effective relative to other health care. Older women are also denied 
funding by reference to “a normal–deviant scale.” Offered in explanation of this 
phrase is the reasoning: “At higher age[s women are] closer to [the] natural fertility 
limit” (Lindström and Waldau 2008, 182). This implies acceptance of the argument 
that infertility in older women represents less of a deviation from the norm than 
infertility in younger women and that thereby older women have less need for ART. 
A “normal functioning range” conception of need underpins this argument, with the 
normal range being identified with fertility naturally declining with female age. 
 
Conclusion 
We have aimed to illuminate conceptual terrain relevant to the question of whether 
ART public funding should feature a female age limit. We have conceptualised that 
question as one of justice in resource allocation and explored arguments for and 
against a female age limit with reference to three much-debated substantive principles 
of justice, namely the capacity to benefit, personal responsibility, and need. Our 
exploration of arguments has included exploring differing conceptions of these 
principles. We have arrived at the following conclusions: 
 Capacity-to-benefit arguments are limited by difficulties in conceptualising 
ART’s benefit and by a lack of data on ART’s age-relative risks of harm, 
which might be taken to offset benefits. 
 As such, there are no clear cost-effectiveness grounds for an age limit when 
older women still bear some capacity to benefit by ART. 
 Personal responsibility arguments are challenged by structural determinants of 
delayed motherhood or, in other words, system factors that may function as 
risk factors for delayed motherhood. 
 Need arguments are capable of speaking both for and against some female age 
restriction depending on the conception of need used. 
We conclude by formulating a series of questions with which the question of ART 
resource allocation might be equated: 
 Should ART public funding vary according to people’s capacity to benefit? 
21 
 
o If so, then at what point? When should ART be considered cost-
ineffective relative to other forms of health care? When should ART be 
considered not merely cost-ineffective but futile and therein more 
harmful than beneficial? 
 Should ART public funding vary according to a person’s degree of 
responsibility for one’s own infertility? 
 Should ART public funding vary according to need? 
o If so, then when is one need greater than another? In other words, what 
constitutes need? Does a person’s need depend on how disrupted one’s 
health is, how important one’s threatened opportunity is, how severe or 
urgent one’s problem is, or some combination? 
 Is female age relevant in determining and comparing (1) people’s capacity to 
benefit from ART, (2) people’s degree of personal responsibility for their 
infertility, and (3) people’s degree of need? If so, then in what respects and to 
what degree? What attributes might be relevant besides female age, and how 
relatively important are they? 
 How relatively important are the capacity to benefit, personal responsibility, 
and need as substantive principles of justice (in other words, bases on which to 
allocate resources)? What other principles, if any, are important, and how 
relatively important are they? 
We have attempted to demonstrate the central relevance of these questions and to 
canvass tenable responses to a number of them. The concepts of capacity to benefit, 
personal responsibility, and need can differ not only in content, but also in what 
relative importance they are accorded in just resource allocation. Wide variation in 
ART public funding policy might be better understood in this light: The variation may 
well reflect differing conceptions of justice with respect to resource allocation. These 
differing conceptions can be observed when comparing some of the more transparent 
ART public funding policies. The relevance of these matters extends beyond ART. 
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Figure 1. Outcomes of IVF cycles by female age group, Australia and New 
Zealand, 2008 (Wang, Chambers, and Sullivan 2010). Autologous success rates 
decline with female age. 
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 The age group of the oocyte recipient, not donor, is plotted. 
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